Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Vascular Spasm01:16

Vascular Spasm

The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Fast, High-Fidelity Addressed Single-Qubit Gates Using Efficient Composite Pulse Sequences.

Physical review letters·2023
Same author

Robust Quantum Memory in a Trapped-Ion Quantum Network Node.

Physical review letters·2023
Same author

Erratum to "Second Consensus on Treatment of Patients Recently Diagnosed with Mild Hypertension and Low Cardiovascular Risk". [YMCD 45/10 (October 2020) 100653].

Current problems in cardiology·2021
Same author

[Certification in cardiology : Contra: The concept should be improved].

Herz·2018
Same author

Higgs physics at the CLIC electron-positron linear collider.

The European physical journal. C, Particles and fields·2017
Same author

[Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

Der Radiologe·2017

関連する実験動画

Updated: Jul 16, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

バソペプチダース阻害剤

M A Weber1

  • 1Office of Scientific Affairs, SUNY Downstate Medical College, State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 97, Brooklyn, NY 11203, USA. mweber@downstate.edu

Lancet (London, England)
|November 14, 2001
PubMed
まとめ

新しいバソペプチダース阻害剤は,高血圧および心不全モデルにおける血圧を下げ,心血管の健康を改善することで,二重作用を提供します. 臨床試験は,多様な集団における有効性を示し,現在の治療法を上回る可能性がある.

科学分野:

  • 心血管薬理学について
  • ドラッグ・ディスカバリー・ディスカバリー・ドラッグ・ディスカバリー・ドラッグ・ディスカバリー
  • 高血圧の研究 高血圧の研究

背景:

  • バソペプチダース阻害剤は,新型の心臓血管薬のクラスです.
  • それらは同時に中性エンドペプチダゼとアンジオテンシン変換酵素 (ACE) を阻害する.
  • この二重抑制は,血管拡張性ペプチドとアンジオテンシンIIの産生を調節する.

研究 の 目的:

  • 血管ペプチダース阻害剤の有効性と安全性を評価する.
  • 高血圧,心不全,不全性心疾患の治療におけるその可能性を評価する.
  • 既存の抗高血圧剤との効果を比較するために.

主な方法:

  • 高血圧,心不全,不全性心疾患の臨床前動物モデルをレビューする.
  • ヒトにおける高血圧と閉塞性心不全に関する臨床試験の分析.
  • 安全性プロファイルと副作用の頻度 (血管腫,咳など) の検討.

主要な成果:

  • 動物モデルでは,バソペプチダース阻害剤は,様々な高血圧のタイプで血圧を低下させ,心不全と不全性心疾患の治療に効果を示した.
  • 人間の研究では,人種や年齢に関係なく,効果的な血圧低下が実証されました.

さらに関連する動画

Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses
07:56

Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses

Published on: June 8, 2022

Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography
09:47

Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography

Published on: August 12, 2022

関連する実験動画

Last Updated: Jul 16, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses
07:56

Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses

Published on: June 8, 2022

Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography
09:47

Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography

Published on: August 12, 2022

  • 主要剤であるオマパトリラットは,現在のACE阻害剤および他の抗高血圧剤よりも高い有効性を示し,心不全にプラスの効果を示した.
  • 結論:

    • バソペプチダース阻害剤は,高血圧と心不全の効果的な治療法として有望であることが示されています.
    • 彼らの安全性プロファイルは,ACE阻害剤と比べられるように見えるが,副作用に関するさらなるデータが必要である.
    • 大規模な臨床エンドポイント試験は,既定の治療法と並行してその役割を定義するために不可欠です.